10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
7.50
-0.02 (-0.20%)
Apr 21, 2025, 10:41 AM EDT - Market open
10x Genomics Revenue
In the year 2024, 10x Genomics had annual revenue of $610.79M, down -1.28%. 10x Genomics had revenue of $165.02M in the quarter ending December 31, 2024, a decrease of -10.30%.
Revenue (ttm)
$610.79M
Revenue Growth
-1.28%
P/S Ratio
1.48
Revenue / Employee
$467,676
Employees
1,306
Market Cap
916.65M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TXG News
- 18 days ago - Vizgen Announces End of Litigation with 10x Genomics and Harvard University - Business Wire
- 4 weeks ago - 10x Genomics: Lower Cost Innovation May Drive A Rebound - Seeking Alpha
- 6 weeks ago - 10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products - PRNewsWire
- 2 months ago - 10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis - PRNewsWire
- 2 months ago - 10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference - PRNewsWire
- 2 months ago - Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties - Benzinga
- 2 months ago - 10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Trump's Cuts to Medical Research Are Hurting These Stocks - Barrons